A randomized, open-label phase II study to evaluate the safety, pharmacokinetics, and efficacy of hepatitis C immune globulin intravenous (Human), Civacir(TM), in liver transplant recipients.

Trial Profile

A randomized, open-label phase II study to evaluate the safety, pharmacokinetics, and efficacy of hepatitis C immune globulin intravenous (Human), Civacir(TM), in liver transplant recipients.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 14 Mar 2017

At a glance

  • Drugs Hepatitis C immune globulin (Primary)
  • Indications Hepatitis C
  • Focus Therapeutic Use
  • Sponsors Biotest Pharmaceuticals; Nabi Biopharmaceuticals
  • Most Recent Events

    • 06 Feb 2012 Additional lead trial investigator identified as reported by ClinicalTrials.gov.
    • 06 Feb 2012 Planned end date changed from 1 Apr 2010 to 1 Feb 2009 as reported by ClinicalTrials.gov.
    • 29 Jun 2010 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top